Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA, Kura Oncology Sign Patient Enrollment Pact

NEW YORK (GenomeWeb) – OncoDNA announced today that it has signed an agreement to provide patient-enrollment services for on ongoing clinical study of Kura Oncology's head and neck squamous cell carcinoma (HNSCC) drug tipifarnib.

Tipifarnib is a protein farnesyl transferase inhibitor originally developed by Johnson & Johnson for a variety of cancers. Kura acquired the oncology rights to the drug in 2015 and is currently testing it in Phase II trials for HNSCC with HRAS mutations, peripheral T cell lymphoma, myelodysplastic syndromes, and chronic myelomonocytic leukemia.

Under the terms of the deal, OncoDNA will help Kura screen for HRAS-mutant HNSCC patients at study sites, as well as support its recruitment efforts by informing physicians with eligible HNSCC patients about potential treatment and clinical trial options.

Additional terms were not disclosed.

"This agreement is in line with our strategy of collaborating with biopharmaceutical companies," OncoDNA CEO Jean-Pol Detiffe said in a statement. "As we develop our business through Europe and beyond, collaborations such as these demonstrate our ability to assist biopharmaceutical companies with their drug-development programs and support the push towards better patient care."

Earlier this month, OncoDNA inked a similar patient-enrollment services deal with BioClin Therapeutics.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.